Adults aged 65 and older who took semaglutide 2.4 mg lost an average of 15.4% of their body weight over 68 weeks, according to a pooled analysis of data from the STEP clinical trial program presented through the European Association for the Study of Obesity. Among the 358 participants in that age group, with a mean age of 69 and a mean BMI of 36, nearly half reached at least 15% total weight loss, compared with just 6.4% of those on placebo. The findings arrive as demand for GLP-1 receptor agonists among older patients is accelerating, but critical questions about muscle preservation and long-term safety in this population remain unanswered.
Why semaglutide results in older adults demand closer scrutiny
The 15.4% average weight reduction in the 65-and-older subgroup closely mirrors the results seen in younger STEP participants, where semaglutide 2.4 mg produced roughly similar percentage losses at the same 68-week mark. That alignment is striking, but it may say as much about trial design as about the drug itself. The STEP trials enrolled adults with overweight or obesity who were otherwise relatively healthy. Participants in the pooled analysis had a mean BMI of 36 and were well enough to complete structured study visits over more than a year. Frail older adults, those with sarcopenia, and people managing multiple chronic conditions were largely absent from these cohorts.
This selection effect matters because the older adults most likely to seek obesity treatment in clinical practice often carry exactly the comorbidities and functional limitations that would have excluded them from STEP enrollment. A drug that works well in a 69-year-old with a BMI of 36 and no disqualifying health problems may perform differently in a 75-year-old managing heart failure, reduced kidney function, and limited mobility. The pooled analysis does not resolve that gap. It confirms efficacy in a carefully screened subset, which is valuable but distinct from proving that the drug works identically across all older age groups.
Another layer of complexity is that aging physiology can alter how GLP-1 receptor agonists are tolerated. Gastrointestinal side effects such as nausea and vomiting may lead to dehydration or electrolyte imbalance more quickly in older adults. In addition, age-related declines in appetite and taste perception can interact with the appetite-suppressing effects of semaglutide, raising the risk of unintentional undernutrition if monitoring is lax. These concerns do not negate the benefits of weight loss but underscore why data from robust, relatively healthy trial participants cannot automatically be generalized to more vulnerable patients.
STEP trial data and the 68-week weight loss threshold
The pooled analysis drew on participants aged 65 and older from multiple STEP trials. Those randomized to semaglutide 2.4 mg lost 15.4% of body weight at week 68, while the placebo group lost 5.1%. The categorical results were equally pronounced: 46.8% of semaglutide-treated participants achieved at least 15% weight loss, versus 6.4% on placebo.
These numbers sit comfortably within the range established by the broader STEP program. The foundational STEP 1 trial tested semaglutide 2.4 mg at 68 weeks in adults without diabetes and set the baseline for efficacy expectations. In that study, participants receiving the active drug lost substantially more weight than those on placebo, with a safety profile dominated by gastrointestinal events that were generally mild to moderate. Those findings helped position semaglutide as a leading pharmacologic option for chronic weight management in adults with obesity or overweight and weight-related comorbidities.
A separate arm of the program, STEP 3, paired semaglutide with intensive behavioral therapy and reported its results in JAMA, showing that structured lifestyle intervention alongside the drug could amplify outcomes. Participants received frequent counseling sessions, calorie goals, and increased physical activity targets in addition to the medication. The combination produced larger average weight reductions and higher proportions of patients reaching clinically meaningful thresholds such as 10% or 15% loss, reinforcing that pharmacotherapy and behavioral support are complementary rather than interchangeable strategies.
Longer-duration data from the STEP 5 trial extended the evidence to 104 weeks, finding sustained mean weight loss of 15.2% with semaglutide versus 2.6% with placebo. That two-year result suggests the effect does not rapidly erode after the first year, provided treatment is continued and patients adhere to lifestyle recommendations. However, the published two-year data do not break out outcomes specifically for adults 65 and older, leaving open the question of whether older participants maintain weight loss to the same degree as younger counterparts over longer horizons.
These efficacy results are consistent with broader clinical experience using GLP-1 receptor agonists for weight management, including earlier agents evaluated in randomized trials. For example, research on liraglutide for obesity documented meaningful weight reduction and improvements in cardiometabolic risk factors, helping establish GLP-1–based therapy as a viable tool for long-term management of excess weight. Semaglutide’s larger effect size builds on that foundation, but the geriatric evidence base remains thinner than the data available for middle-aged adults.
Gaps in geriatric evidence for semaglutide weight loss
The most consequential gap is body composition. Older adults who lose weight rapidly risk losing lean muscle mass alongside fat, a process that can accelerate functional decline and increase fall risk. None of the published STEP trial papers provide separate adverse-event tables, sarcopenia measures, or body-composition breakdowns for participants aged 65 and older. A systematic review focused on antiobesity medications in older adults confirmed that direct geriatric evidence remains limited across the drug class, not just for semaglutide. Without granular data on how much of the 15.4% weight loss came from fat versus muscle, clinicians are left making treatment decisions based on total scale weight alone.
Dosing adjustments and discontinuation patterns in older patients are similarly unreported. The STEP trials used a standardized dose-escalation protocol, but real-world prescribing for a 70-year-old with reduced renal clearance or multiple medications often involves slower titration, dose pauses, or maintaining a lower-than-maximal dose to preserve tolerability. The pooled analysis in adults 65 and older does not detail how many participants required dose reductions, how frequently treatment was interrupted, or whether older adults stopped therapy at higher rates than younger cohorts. Those missing data points are crucial for understanding how the drug performs outside the controlled environment of a clinical trial.
Safety signals specific to older age are also under-characterized. While no major new concerns have emerged in the pooled STEP data, the absence of age-stratified reporting on events such as gallbladder disease, pancreatitis, or gastrointestinal complications limits clinicians’ ability to counsel older patients accurately. Even modest increases in these risks could have outsized consequences in people with frailty, polypharmacy, or limited physiologic reserve.
Implications for clinical practice in older adults
For now, the STEP findings support offering semaglutide to carefully selected older adults with obesity, particularly those with weight-related conditions such as type 2 diabetes, sleep apnea, or osteoarthritis in whom weight reduction could substantially improve quality of life. However, the decision to start therapy should be individualized and anchored in a broader geriatric assessment that includes functional status, fall risk, nutritional intake, and patient goals.
Clinicians may reasonably adopt a more cautious approach to dose escalation in adults 65 and older, prioritizing tolerability over rapid weight loss. Close monitoring of hydration, appetite, and unintentional reductions in protein intake is essential, as is encouraging resistance training and adequate dietary protein to support muscle preservation. Regular reassessment of functional measures-such as gait speed, grip strength, and ability to perform activities of daily living-can help detect early signs that weight loss is undermining rather than enhancing health.
Shared decision-making is central. Some older adults may place highest value on relief from joint pain or improved mobility, even if that entails potential side effects and the burden of weekly injections. Others may prioritize maintaining strength and independence over aggressive weight reduction. In the absence of definitive geriatric data, transparent discussion of uncertainties-especially around muscle mass and long-term safety-is ethically necessary.
The pooled STEP analysis in adults 65 and older demonstrates that semaglutide can deliver substantial weight loss in this age group under trial conditions. Yet the lack of detailed body-composition data, limited reporting on age-specific safety and tolerability, and the exclusion of frail or highly comorbid patients leave important questions unanswered. As use of GLP-1 receptor agonists expands among older adults, future research will need to move beyond overall percentages on the scale and focus on what matters most in geriatric care: preserving function, independence, and quality of life while minimizing harm.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
